|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
260,040,000 |
Market
Cap: |
104.57(B) |
Last
Volume: |
1,256,271 |
Avg
Vol: |
1,619,368 |
52
Week Range: |
$323.57 - $446.08 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 543 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
67,740 |
146,629 |
258,193 |
599,091 |
Total Sell Value |
$28,555,052 |
$59,794,343 |
$99,413,137 |
$200,179,521 |
Total People Sold |
8 |
12 |
15 |
18 |
Total Sell Transactions |
28 |
40 |
68 |
131 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Sanna Bastiano |
EVP, Cell & Genetic Therapies |
|
2023-02-17 |
4 |
D |
$292.85 |
$1,098,188 |
D/D |
(3,750) |
55,984 |
|
- |
|
Wagner Charles F Jr |
EVP & Chief Financial Officer |
|
2023-02-17 |
4 |
D |
$292.85 |
$1,098,188 |
D/D |
(3,750) |
61,441 |
|
- |
|
Bozic Carmen |
EVP and CMO |
|
2023-02-17 |
4 |
D |
$292.85 |
$1,098,188 |
D/D |
(3,750) |
66,515 |
|
- |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2023-02-17 |
4 |
D |
$292.85 |
$1,317,239 |
D/D |
(4,498) |
60,947 |
|
- |
|
Altshuler David |
EVP, Global Research and CSO |
|
2023-02-17 |
4 |
D |
$292.85 |
$1,098,188 |
D/D |
(3,750) |
44,248 |
|
- |
|
Sachdev Amit |
EVP, Chief Patient Officer |
|
2023-02-17 |
4 |
D |
$292.85 |
$1,024,389 |
D/D |
(3,498) |
68,986 |
|
- |
|
Sanna Bastiano |
EVP, Cell & Genetic Therapies |
|
2023-02-14 |
4 |
AS |
$300.29 |
$655,161 |
D/D |
(2,181) |
59,734 |
|
16% |
|
Arbuckle Stuart A |
EVP, COO |
|
2023-02-14 |
4 |
AS |
$295.84 |
$1,910,962 |
D/D |
(6,398) |
75,605 |
|
16% |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2023-02-14 |
4 |
AS |
$295.89 |
$95,527 |
D/D |
(320) |
65,445 |
|
16% |
|
Altshuler David |
EVP, Global Research and CSO |
|
2023-02-14 |
4 |
AS |
$295.79 |
$1,911,108 |
D/D |
(6,398) |
47,998 |
|
16% |
|
Altshuler David |
EVP, Global Research and CSO |
|
2023-02-13 |
4 |
AS |
$296.44 |
$1,434,126 |
D/D |
(4,798) |
54,396 |
|
16% |
|
Altshuler David |
EVP, Global Research and CSO |
|
2023-02-13 |
4 |
D |
$298.26 |
$1,786,577 |
D/D |
(5,990) |
59,194 |
|
- |
|
Sanna Bastiano |
EVP, Cell & Genetic Therapies |
|
2023-02-13 |
4 |
AS |
$300.39 |
$33,944 |
D/D |
(113) |
61,915 |
|
16% |
|
Sanna Bastiano |
EVP, Cell & Genetic Therapies |
|
2023-02-13 |
4 |
D |
$298.26 |
$1,294,448 |
D/D |
(4,340) |
62,028 |
|
- |
|
Sachdev Amit |
EVP, Chief Patient Officer |
|
2023-02-13 |
4 |
D |
$298.26 |
$1,388,997 |
D/D |
(4,657) |
72,484 |
|
- |
|
Bozic Carmen |
EVP and CMO |
|
2023-02-13 |
4 |
D |
$298.26 |
$1,488,914 |
D/D |
(4,992) |
70,265 |
|
- |
|
Arbuckle Stuart A |
EVP, COO |
|
2023-02-13 |
4 |
AS |
$296.44 |
$1,460,816 |
D/D |
(4,887) |
82,003 |
|
16% |
|
Arbuckle Stuart A |
EVP, COO |
|
2023-02-13 |
4 |
D |
$298.26 |
$1,786,577 |
D/D |
(5,990) |
86,890 |
|
- |
|
Leiden Jeffrey M |
Executive Chairman |
|
2023-02-13 |
4 |
D |
$298.26 |
$3,979,981 |
D/D |
(13,344) |
62,079 |
|
- |
|
Kewalramani Reshma |
CEO & President |
|
2023-02-13 |
4 |
D |
$298.26 |
$1,786,577 |
D/D |
(5,990) |
148,714 |
|
- |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2023-02-13 |
4 |
AS |
$295.84 |
$82,223 |
D/D |
(275) |
65,765 |
|
16% |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2023-02-13 |
4 |
D |
$298.26 |
$893,289 |
D/D |
(2,995) |
66,040 |
|
- |
|
Wagner Charles F Jr |
EVP & Chief Financial Officer |
|
2023-02-13 |
4 |
D |
$298.26 |
$1,488,914 |
D/D |
(4,992) |
65,191 |
|
- |
|
Altshuler David |
EVP, Global Research and CSO |
|
2023-02-10 |
4 |
D |
$294.33 |
$1,018,676 |
D/D |
(3,461) |
65,184 |
|
- |
|
Sanna Bastiano |
EVP, Cell & Genetic Therapies |
|
2023-02-10 |
4 |
D |
$294.33 |
$265,486 |
D/D |
(902) |
66,368 |
|
- |
|
1777 Records found
|
|
Page 8 of 72 |
|
|